Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.59 |
| ▸ | PKM | P14618 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | PTPN2 | P17706 | 2/20 | 0.51 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.51 |
| ▸ | PTPN5 | P54829 | 2/20 | 0.51 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | ALPL | P05186 | 4/20 | 0.48 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7499285 | 0.89 | BRD4 (0.61) | TP53PKMHTTBRD4SMN1; SMN2 | |
| SCHEMBL7541848 | 0.89 | PKM (0.67) | TP53PKMHTTLMNAIDH1 | |
| SCHEMBL7533432 | 0.88 | ALDH1A1 (0.53) | TP53PKMLMNABRD4BRPF1 | |
| SCHEMBL15999617 | 0.88 | TP53 (0.70) | TP53PKMHTTNPSR1LMNA | |
| SCHEMBL7501360 | 0.86 | BRD4 (0.57) | TP53PKMHTTBRD4SMN1; SMN2 | |
| SCHEMBL7534833 | 0.84 | ALDH1A1 (0.53) | TP53PKMLMNABRD4BRPF1 | |
| SCHEMBL7501770 | 0.84 | TP53 (0.55) | TP53PKMHTTBRD4SMN1; SMN2 | |
| SCHEMBL7507552 | 0.82 | TSHR (0.59) | TP53PKMHTTBRD4SMN1; SMN2 | |
| SCHEMBL7536210 | 0.81 | PKM (0.54) | TP53PKMHTTLMNABRD4 | |
| SCHEMBL7534803 | 0.80 | PKM (0.57) | TP53PKMHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170007608-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS INC (US) | 2017-01-12 | — | — | US | disclosed |
| EP-2427441-B1 | PKM2 ACTIVATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2016-12-14 | — | — | EP | disclosed |
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | AGIOS PHARMACEUTICALS, INC (US) | 2014-09-04 | — | — | US | disclosed |
| US-8501953-B2 | PKM2 modulators for use in the treatment of cancer | AGIOS PHARMACEUTICALS, INC (US) | 2013-08-06 | — | — | US | disclosed |
| WO-2013056153-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | KUNG CHARLES (US) | 2013-04-18 | — | — | WO | disclosed |
| US-20120122849-A1 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. | 2012-05-17 | — | — | US | disclosed |
| WO-2010129596-A1 | PMK2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122849-A1 | PKM2 MODULATORS FOR USE IN THE TREATMENT OF CANCER | PDK2, PDK1, PDK3 | TP53 302/4885PKM 5/4885HTT 4166/4885 |
| US-20140249150-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | TP53 722/4885PKM 11/4885HTT 2863/4885 |
| US-20170007608-A1 | ACTIVATORS OF PYRUVATE KINASE M2 AND METHODS OF TREATING DISEASE | PDK1, PC, PDK2 | TP53 722/4885PKM 11/4885HTT 2863/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.